Smith & Nephew Plc is a global leader in medical and dental products, headquartered at Building 5, Croxley Park, Watford, UK. Established in 1937, the company specializes in the design, manufacture, and distribution of a broad portfolio of orthopaedic, surgical, and diagnostic instruments, implants, and supplies. Currently, Smith & Nephew operates as an active company with a significant international presence, serving customers across numerous regions. The company’s core business focuses on providing solutions for healthcare professionals, including surgeons, dentists, and specialists. In Q1 2025, Smith & Nephew reported annual revenues of $1.407 billion, exhibiting a 3.1% underlying growth driven primarily by U.S. implant sales, which contributed to overall gains. However, China’s market performance was negatively impacted, resulting in a slight decrease in sales. The company’s strategic focus remains on innovation and market expansion within its key therapeutic areas. As an active company, Smith & Nephew is a global business mobility visa holder, rated as a Worker (A rating). The company’s SIC codes encompass the manufacturing of other chemical products n.e.c., basic pharmaceutical products, and medical and dental instruments and supplies.

Smith & Nephew Plc is a global leader in medical and dental products, headquartered at Building 5, Croxley Park, Watford, UK. Established in 1937, the company specializes in the design, manufacture, and distribution of a broad portfolio of orthopaedic, surgical, and diagnostic instruments, implants, and supplies. Currently, Smith & Nephew operates as an active company with a significant international presence, serving customers across numerous regions. The company’s core business focuses on providing solutions for healthcare professionals, including surgeons, dentists, and specialists. In Q1 2025, Smith & Nephew reported annual revenues of $1.407 billion, exhibiting a 3.1% underlying growth driven primarily by U.S. implant sales, which contributed to overall gains. However, China’s market performance was negatively impacted, resulting in a slight decrease in sales. The company’s strategic focus remains on innovation and market expansion within its key therapeutic areas. As an active company, Smith & Nephew is a global business mobility visa holder, rated as a Worker (A rating). The company’s SIC codes encompass the manufacturing of other chemical products n.e.c., basic pharmaceutical products, and medical and dental instruments and supplies.